Dabo Medical Technology Co., Ltd. (stock code: 002901) is a company specializing in the production, R & D and sales of high-value medical consumables. The company's main products are widely used in fracture repair, spinal disease treatment, joint replacement, sports medicine and oral implants and other fields. Some changes have taken place in the company's financial position in the semi-annual report of 2023.

First of all, as can be seen from the balance sheet, Dabo Medical's total assets at the end of the period totaled 4.315 billion yuan, an increase compared with 3.938 billion yuan at the beginning of the period. The total debt increased from 831 million yuan at the beginning of the period to 1.121 billion yuan at the end of the period. This indicates that the company's assets and liabilities increased during the reporting period. At the same time, the company's asset-liability ratio rose from 21.11% at the beginning of the period to 25.97% at the end of the period, which means that the company's debt level has increased.

In terms of profit, the company's gross profit margin fell from 80.97% in the same period last year to 69.68% in the current reporting period, and the net profit margin also fell from 22.8% in the same period last year to 13.57% in the current reporting period. This may mean that the company's profitability is under some pressure. At the same time, the company's net profit fell from 189 million yuan in the same period last year to 102 million yuan in the current reporting period, which further confirmed the decline in the company's profitability.

The company's net assets increased from 3.106 billion yuan at the beginning of the period to 3.194 billion yuan at the end of the period, indicating a steady growth of the company's net assets. However, the return on assets (ROE) fell from 6.63 per cent at the beginning of the period to 3.23 per cent at the end of the period, which may mean that the company's asset use efficiency has declined.

In terms of goodwill, the company's final balance of 687 million yuan, compared with the beginning of the 691 million yuan, little change, indicating the company's stability in goodwill.

Overall, the financial situation of Dabo Medical presented some challenges in the first half of 2023. Although the company's net assets grow steadily and its goodwill is stable, its profitability and efficiency in the use of assets have declined, and its debt level has also increased. This may mean that companies need to pay more attention to the improvement of their profitability and efficiency in the use of assets in the future, while controlling the level of debt to maintain the soundness of their financial position. For investors, it is necessary to pay close attention to the financial situation and business development of Dabo Medical, and make wise investment decisions.

This article only represents the judgment made by the analyst himself or the analyst on the basis of AI analysis, and can not be used as any investment index, nor does it constitute any investment advice. The original intention of this paper is to help investors analyze and judge the capital market data in the most intuitive and fast way and from the most professional perspective.